– UK, Cambridge – Cambridge Epigenetix, a life sciences tools and technology company which is revolutionizing genome sequencing, today announced the appointment of Peter Fromen as CEO effective July 18, 2022, replacing Gail Marcus who has been acting CEO since 2020 and will continue as Chair of the Board of Directors.
Professor Sir Shankar Balasubramanian FRS, the co-founder of Cambridge Epigenetix, said, “We welcome Peter and his vast industry experience and valuable relationships to lead Cambridge Epigenetix at this critical juncture. The founders, Gail, and the entire Board are delighted to have Peter’s leadership as we seek to grow the company into its full potential.”
“Peter brings global leadership and broad commercial expertise leading key functions in product marketing, product management, market development, sales, service, and support. His record of building, growing, and retaining world-class teams is particularly important to us as we prepare for the future,” said Gail Marcus. “We are confident Peter and his leadership style will enhance our innovation-centric culture which- is built on integrity, humility, and diversity.”
About Peter J. Fromen
Mr. Fromen joins the company from PacBio (NASDAQ: PACB) where he served as CCO, based in London. During his tenure, he transformed the commercial organization and led the team to achieve record levels of sales, growing revenues by 65% and more than doubling the company’s installed base of sequencers.
Before PacBio, Mr. Fromen worked at Illumina where he held numerous leadership positions across the finance and commercial organizations including investor relations, product marketing, market development, and enterprise sales. He built the Company’s first investor relations and market development functions and had a leading role in launching the Company’s HiSeq X Ten Sequencing System which delivered the first $1000 human whole genome. Notably, while serving as the company’s Global VP of Population Genomics and Precision Health, Mr. Fromen oversaw Illumina’s partnership with Genomics England and the National Health System to execute the 100,000 Genomes Project which subsequently led to the commissioning of whole-genome sequencing in the NHS for rare disease and certain cancers.
“The founders of Cambridge Epigenetix had the foresight and wisdom to envision the potential of epigenetics before anyone else, attracting an industry-leading Board and group of investors. This exceptional team has developed one of the most exciting technology platforms I have seen in my career. It has the potential to dramatically reduce the cost of capturing novel epigenetic information while preserving its genetic context, all in a single sequencing workflow,” said Peter Fromen. “I am deeply excited to join Cambridge Epigenetix and lead the company to its next stage of growth, empowering customers to realize the full contribution of epigenetics to human health.”
About Cambridge Epigenetix
Cambridge Epigenetix, a life sciences tools and technology company, is revolutionizing sequencing by delivering new dimensions of information from DNA to identify and treat disease earlier, harnessing the potential to transform life sciences and medicine. The commercial-stage company’s platform provides more information with greater efficiency at higher quality and lower cost than standard next-generation sequencing technologies. Easily integrating into existing sequencers, the company’s products allow the user to simultaneously see genetic and epigenetic information in a single workflow. This information can be used to detect, diagnose, treat, and understand the disease. Based in Cambridge, UK, among the Company’s founders is a pioneer in DNA sequencing, intent on leading the next great leap forward in genomics.
For more information: https://cambridge-epigenetix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
